Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Alignment Healthcare's chief experience officer sells shares worth over $21k

Published 03/15/2024, 08:01 PM
Updated 03/15/2024, 08:01 PM
© Reuters.

Alignment Healthcare, Inc. (NASDAQ:ALHC) has reported a recent transaction involving its Chief Experience Officer, Hakan Kardes, who sold shares in the company. On March 15, 2024, Kardes sold 4,326 shares of common stock at a weighted-average price ranging from $4.77 to $5.06, with the total value of the sale amounting to approximately $21,158.

The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units, as noted in the footnotes of the transaction report. This was not a discretionary trade by Kardes but rather a transaction mandated by the vesting terms of the restricted stock units. The shares sold were part of a larger holding following a series of transactions that included grants of restricted stock units and fully vested shares.

It's important to note that these transactions are part of the standard compensation and tax-related practices within the company. Following the sale, Kardes still holds a significant number of shares, totaling 453,771, demonstrating continued investment in the company's future.

Investors and followers of Alignment Healthcare, Inc. should be aware that executives' stock transactions can be routine and are often scheduled in advance or triggered by specific events such as vesting schedules. These transactions are disclosed to provide transparency and maintain compliance with securities regulations.

InvestingPro Insights

Alignment Healthcare, Inc. (NASDAQ:ALHC) has been navigating a challenging market environment, as reflected in some key metrics from InvestingPro. The company's market capitalization stands at 943 million USD, indicating a mid-sized player within its sector. Despite a significant revenue growth of 27.16% over the last twelve months as of Q1 2023, the company's profitability remains under scrutiny. The adjusted P/E ratio for the same period is -6.43, reinforcing the sentiment that profitability is a concern. Moreover, the stock's performance has seen a downturn, with a 3-month price total return of -37.07%.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Of note for investors, Alignment Healthcare holds more cash than debt on its balance sheet, which can be a positive sign of financial stability. However, it is essential to consider that analysts have revised their earnings expectations downwards for the upcoming period, which could impact future stock performance. Furthermore, the company is trading at a high Price / Book multiple of 6.01, which could suggest that the stock is valued richly in relation to its net assets.

These financial insights may be particularly relevant for investors in light of the recent insider transaction. While the sale by Chief Experience Officer Hakan Kardes was for tax purposes, the broader financial context provided by InvestingPro can help investors better understand the company's current position and future prospects. For those looking to delve deeper into Alignment Healthcare's financial health and stock performance, there are additional InvestingPro Tips available, including insights on the company's valuation multiples and profitability outlook. By using the coupon code PRONEWS24, investors can get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking access to a wealth of financial data and expert analysis.

For a more comprehensive analysis, investors can explore the full suite of 9 InvestingPro Tips for Alignment Healthcare at https://www.investing.com/pro/ALHC, which could provide further guidance on whether the stock aligns with their investment strategy.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.